IL1B and type 1 diabetes mellitus: The adverse effects of IL-1β on human beta cells in vitro and in animal models have promoted recent clinical trials in volunteers with recent-onset type 1 diabetes, using strategies involving the systemic blockade of IL-1β or its receptors [7,11].